CanSino Biologics in China conducted the first trial of the first coronavirus vaccine to humans. Results of the study published on Friday in The Lancet indicate that the vaccine is “tolerable and immunogenic to healthy adults”. The findings suggest that the vaccine, which was introduced to adults with the age range of 18-60 years old through intramuscular injection, can recognize the virus and produce an immune response.
Based on the blood sample from the vaccinated adults, the production of neutralizing and ELISA antibodies peaked at 28 days after the vaccination while the virus-specific T-Cell response peaked at day 14 after the vaccination. The immune response triggered by the vaccine, however, does not determine the certainty that the vaccine can protect against the virus. Researchers suggest further investigation on using the vaccine to fight VOCID-19.The second phase of the testing will also be conducted in China following the milestone achieved by using recombinant adenovirus type-5 vectored COVID-19 vaccine.
There are no serious adverse reactions from those who were vaccinated. However, there is at least an instance of recorded adverse reaction from 83% of those in the low-dose group in the first seven days after the vaccination.The most common adverse reactions were fatigue, headache,fever, and muscular pain.